Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1997 1
1998 1
1999 4
2002 2
2003 1
2007 1
2008 1
2012 1
2013 1
2015 1
2017 2
2018 3
2019 6
2020 7
2021 4
2022 5
2023 6
2024 2
2025 6
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean T. M. nagarajan (134 results)?
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.
Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe SW, Rangarajan S, Shen MC, Srivastava A, Sun J, Tran H, You CW, Zülfikar B, Menapace LA, Zhang C, Shen Y, Puurunen M, Demissie M, Kenet G. Young G, et al. Blood. 2025 Jun 19;145(25):2966-2977. doi: 10.1182/blood.2024027008. Blood. 2025. PMID: 40053895 Free PMC article. Clinical Trial.
Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study.
Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, Zahr F, Chadderdon S, Fam N, Ong G, Yadav P, Thourani V, Vannan MA, O'Neill WW, Wang DD, Tchétché D, Dumonteil N, Bonfils L, Lepage L, Smith R, Grayburn PA, Sharma RP, Haeffele C, Babaliaros V, Gleason PT, Elmariah S, Inglessis-Azuaje I, Passeri J, Herrmann HC, Silvestry FE, Lim S, Fowler D, Webb JG, Moss R, Modine T, Lafitte S, Latib A, Ho E, Goldberg Y, Shah P, Nyman C, Rodés-Cabau J, Bédard E, Brugger N, Sannino A, Mack MJ, Leon MB, Windecker S; the TRISCEND study investigators. Kodali S, et al. Eur Heart J. 2023 Dec 7;44(46):4862-4873. doi: 10.1093/eurheartj/ehad667. Eur Heart J. 2023. PMID: 37930776

New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P < .001), and six-minute walk distance increased by 56.2 m (P < .001). All-cause mortality was 9.1%, and 10.2% of p

…

New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardiomyopathy Questionnaire score increased by 25

…
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K. Patil VM, et al. Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31. Cancer. 2019. PMID: 31150120 Free article. Clinical Trial.
Adult patients with locally advanced head and neck cancer who were fit for radical chemoradiation were randomized 1:1 to receive either radical radiotherapy (66-70 grays) with concurrent weekly cisplatin (30 mg/m(2) ) (CRT) or the same schedule of CRT with weekly nimotuzum …
Adult patients with locally advanced head and neck cancer who were fit for radical chemoradiation were randomized 1:1 to receive either radi …
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Jaiswal AK, Khan A, Sundharam M, Vaibhaw A, Saroha A, Rajyopadhye S, Basu M, Asija S, Chowdhury A, Beher R, Banik A, Dwivedi A, Purwar S, Narula G, Banavali S, Jain N, Highfill SL, Stroncek D, Fry T, Melinkeri S, Wilson L, Agarwal N, Aribandi A, Boyella PK, Shah NN, Neelapu SS, Sengar M, Purwar R; CAR-T clinical trial group. Jain H, et al. Lancet Haematol. 2025 Apr;12(4):e282-e293. doi: 10.1016/S2352-3026(24)00377-6. Epub 2025 Mar 13. Lancet Haematol. 2025. PMID: 40090352 Clinical Trial.
Patients underwent apheresis to obtain at least 1 10(9) lymphocytes to manufacture CAR T cells. Lymphodepletion therapy was done with cyclophosphamide 500 mg/m(2) and fludarabine 30 mg/m(2) for 3 days or bendamustine 90 mg/m(2) for 2 days. Patients w …
Patients underwent apheresis to obtain at least 1 10(9) lymphocytes to manufacture CAR T cells. Lymphodepletion therapy was done wi …
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.
Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ. Wudhikarn K, et al. Blood Adv. 2025 Nov 11;9(21):5460-5472. doi: 10.1182/bloodadvances.2025016141. Blood Adv. 2025. PMID: 40435511 Free PMC article.
Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, ris …
Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-ce …
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.
Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ. Rangarajan HG, et al. Blood Adv. 2025 Nov 11;9(21):5489-5500. doi: 10.1182/bloodadvances.2025016149. Blood Adv. 2025. PMID: 40737539 Free PMC article.
Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). ...
Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acut …
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Alexander JL, Dávila Saldaña BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing JJ, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JA, Rayes A, Madden L, Shereck E, Miller HK, Satter LF, Martinez C, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen A, Chong H, Chopek A, Gillio AP, Joshi A, Rangarajan H, Moore TB, Andolina JR, DeSantes KB, Vander Lugt M, Prockop SE, Shyr DC, Sullivan KE, Parikh S, Weinacht KG, Torgerson TR, Marsh R, Dvorak CC, Chan AY, Haddad E, Heimall JR, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM. Alexander JL, et al. Blood Adv. 2026 Mar 10;10(5):1783-1798. doi: 10.1182/bloodadvances.2025017662. Blood Adv. 2026. PMID: 41346295 Free PMC article.
Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non-busulfan-based regimens were used. ...
Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non-busulfan-based regime …
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.
Leiding JW, Arnold DE, Parikh S, Logan B, Marsh RA, Griffith LM, Wu R, Kidd S, Mallhi K, Chellapandian D, Si Lim SJ, Grunebaum E, Falcone EL, Murguia-Favela L, Grossman D, Prasad VK, Heimall JR, Touzot F, Burroughs LM, Bleesing J, Kapoor N, Dara J, Williams O, Kapadia M, Oshrine BR, Bednarski JJ, Rayes A, Chong H, Cuvelier GDE, Forbes Satter LR, Martinez C, Vander Lugt MT, Yu LC, Chandrakasan S, Joshi A, Prockop SE, Dávila Saldaña BJ, Aquino V, Broglie LA, Ebens CL, Madden LM, DeSantes K, Milner J, Rangarajan HG, Shah AJ, Gillio AP, Knutsen AP, Miller HK, Moore TB, Graham P, Bauchat A, Bunin NJ, Teira P, Petrovic A, Chandra S, Abdel-Azim H, Dorsey MJ, Birbrayer O, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Malech HL, Kang EM. Leiding JW, et al. Blood. 2023 Dec 14;142(24):2105-2118. doi: 10.1182/blood.2022019586. Blood. 2023. PMID: 37562003 Free PMC article.
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.
Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H. Jolly MK, et al. Pharmacol Ther. 2019 Feb;194:161-184. doi: 10.1016/j.pharmthera.2018.09.007. Epub 2018 Sep 28. Pharmacol Ther. 2019. PMID: 30268772 Review.
Furthermore, these hybrid E/M cells may possess higher tumor-initiation and metastatic potential as compared to cells on either end of the EMT spectrum. ...Together, these studies drive the emerging notion that cells in a hybrid E/M phenotype may occupy 'metastatic …
Furthermore, these hybrid E/M cells may possess higher tumor-initiation and metastatic potential as compared to cells on either end o …
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.
Pidala J, Kim J, Kalos D, Cutler C, DeFilipp Z, Flowers MED, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko C, Ponce D, Sung A, Tang H, Farhadfar N, Nemecek E, Pusic I, Qayed M, Rangarajan H, Hogan W, Etra A, Jaglowski S. Pidala J, et al. Blood Adv. 2025 Mar 11;9(5):1040-1048. doi: 10.1182/bloodadvances.2024014374. Blood Adv. 2025. PMID: 39454280 Free PMC article.
58 results